For physicians and residents. Educational decision support based on published evidence and recommendations. It does not establish a diagnosis, operability decision, prescription or treatment plan and does not replace thoracic MDT judgement. Privacy: Case data are processed locally in this browser and are not transmitted to, stored by, or accessible to radioterapie.eu. If the host provides no country header, the server may use the visitor’s public IP only to retrieve an approximate country code; no case data are involved.

Lung Cancer Evidence Navigator

Adult NSCLC and SCLC routing from diagnosis through surgery, radiotherapy, systemic-treatment coordination, metastatic disease, brain management and survivorship.

🔒 Case stays on this deviceNo server-side case storageTNM 9 recorded, not derivedEuropean core + national overlayEvidence snapshot 25 Aug 2026v1.0 RC2.2

How to use1 Enter the disease state · 2 Resolve staging, fitness and safety blockers · 3 Review the interpretation · 4 Save, print or hand off.

Practice contextEuropean evidence core + transparent national source layer

European evidence core selected.

Core case inputs and decision-changing items. Detailed anatomy and teaching notes stay out of the way.

RC2 scope: adult NSCLC and SCLC; diagnostic/staging completion; operability and RT feasibility; postoperative, early, stage III, oligometastatic/oligoprogressive, brain and palliative routing. Mesothelioma, thymic, neuroendocrine tumours other than SCLC, paediatric disease and exact systemic sequencing are handed off. National source coverage is reported separately from deterministic rules; “Not computed” never means agreement.

Regression tests not run

Use “Run self-tests” above.

1. Clinical situation

Route histology and disease state first. Record the clinician-verified TNM 9 stage; this module does not reproduce or derive staging tables.

Case

Disease family

Histopathology

Disease state

TNM edition

Reported stage group not derived

Why stage is recorded rather than computed

TNM 9 changed nodal and metastatic subcategories. This release records the verified edition, descriptors and stage group without copying copyrighted tables or inferring a group from incomplete data.

2. Diagnostic work-up, operability and fitness

Separate anatomical staging, pathological confirmation, technical resectability and physiological operability.

Work-up

Contrast CT thorax/upper abdomen

FDG PET/CT

Brain imaging

Pathological diagnosis

Mediastinal staging

Thoracic MDT review

ECOG PS

Frailty / vulnerability

Operability decision

FEV1 % predicted

DLCO % predicted

Cardiopulmonary assessment

3. Predictive biology and systemic-treatment hand-off

Record actionable drivers and PD-L1 before the pathway requires them; this module does not invent a drug sequence.

Biology

Broad molecular profiling

EGFR

ALK

ROS1

BRAF V600E

KRAS G12C

MET exon 14

RET

NTRK

HER2 mutation

PD-L1 TPS %

Systemic-treatment status

4. Surgery and pathological risk

Keep margin status, pathological nodes and prior perioperative therapy separate; postoperative RT is not a reflex response to pN2.

Pathology

Resection

Margin

Pathological T

Pathological N

Positive nodes

Involved nodal stations

Extranodal/extracapsular extension

Perioperative systemic therapy

5. Radiotherapy anatomy and safety

Location, size, motion, interstitial lung disease and prior dose determine whether an apparently simple thoracic RT pathway is actually safe.

RT safety

Lesion location

Maximum diameter cm

Respiratory motion assessed Image guidance / verification planned

Interstitial lung disease

Supplemental oxygen

Prior overlapping thoracic RT

Expected overlap

Prior RT date

Prior prescription/site

Prior plan/dose available

Open BED/EQD2 Workbench →Composite dose support only; thoracic re-irradiation requires expert review.

Open local RT Prescription Navigator →The disease module transfers intent and constraints, not an automatically authorised prescription.

6. Metastatic, brain and SCLC-specific state

Separate baseline oligometastatic disease, oligoprogression, symptomatic palliation and SCLC limited/extensive-stage decisions.

Advanced

Extracranial metastases

Metastatic organs

All known sites safely treatable locally

Systemic disease control

Brain metastases

Neurological symptoms

SCLC extent

SCLC response

Residual thoracic SCLC

PCI / MRI strategy

Symptomatic thoracic/distant disease needing palliation

Current treatment goal

7. Follow-up, trials and source layer

Surveillance, smoking cessation, rehabilitation and trial hand-off remain linked to histology, stage and treatment.

Follow-up

Case timeline

Diagnosis date

Surgery date

RT start

Response assessment

Clinical trials

Links open external registries with disease-family search terms only. No case details or identifiers are transmitted.

Primary evidence and access layer